UpCard-CA1 (Torsemide) Oral Solution is a potent loop diuretic prescribed for once-daily administration to manage pulmonary edema in dogs with congestive heart failure caused by myxomatous mitral valve disease (MMVD). It is indicated for use in combination with concurrent therapies, including pimobendan, spironolactone, and an angiotensin-converting enzyme (ACE) inhibitor, to effectively treat pulmonary edema and help keep dogs healthy with MMVD-related congestive heart failure.How it Works

UpCard-CA1 (torsemide oral solution) is a loop diuretic of the pyridyl sulfonylurea class. Loop diuretics mainly inhibit the Na+/2Cl-/K+ carrier in the ascending limb of the loop of Henle. UpCard-CA1 is an oral solution of 0.2% w/v torsemide in an aqueous mixture containing tromethamine, hydroxyethyl cellulose, saccharin sodium, and propylene glycol.

Special Precautions

User Warnings: Not for use in humans. Keep this and all medications out of the reach of children. Wash hands after use and/or spillage. In case of accidental human ingestion, seek medical advice immediately and show package insert or the label to the physician. Symptoms of exposure to torsemide may include dryness of the mouth, thirst, weakness, lethargy, drowsiness, restlessness, muscle pains or cramps, muscular fatigue, hypotension, oliguria, tachycardia, nausea, or vomiting. Animal Warnings: The administration of UpCard-CA1, a loop diuretic, may lead to excessive diuresis which could result in electrolyte imbalance, dehydration, and reduction of plasma volume enhancing the risk of circulatory collapse, thrombosis, and embolism. Dogs receiving UpCard-CA1 should be observed for signs of fluid depletion with electrolyte imbalance. UpCard-CA1 is for use only in stable dogs with congestive heart failure caused by MMVD. A diagnosis of MMVD should be made by means of a comprehensive physical and cardiac examination. The safe administration of UpCard-CA1 relies on regular assessment of treated dogs for the clinical signs of pulmonary edema and potential treatment-related adverse events. Physical examination, hydration status, BUN, serum creatinine, and serum electrolytes should be assessed prior to the initiation of therapy or dose adjustment, and at 24 hours and 48 hours after the start of therapy or dose adjustment.

Overdose Information

Contact the nearest emergency animal hospital

Side Effects

In a multi-site European clinical field study, 251 client-owned dogs suffering from edema secondary to congestive heart failure were treated with at least one dose of a tablet formulation of torsemide (n=126) or furosemide (n=125) for a 3-month treatment period. A greater overall frequency of adverse reactions was recorded in the torsemide group (n=184 events) compared with furosemide treated dogs (n=104 events). The most common reactions involved the urinary system, including polyuria and polydipsia, renal insufficiency, increased BUN and serum creatinine and urinary incontinence. See the package insert or the label for full results.

Storage

Store at or below 30°C (86°F). Excursions permitted between 4°C - 40°C (39°F-104°F). Discard 90 days after opening.